OTC: ETST

Earth Science Tech, Inc.

CIK 0001538495 · SIC 2834 · Pharmaceutical Preparations

Micro Revenue $36M Assets $10M as of Sep 13, 2026

Earth Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April 23, 2010, and subsequently redomiciled to the State of Florida on June 27, 2022, headquartered in Miami, Florida. About this business →

Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.

Sign up free

Want to see a complete report first? Today's free report (GIS 10-Q) is open in full — no account needed.

8-K Filed Sep 1, 2026 · Period ending Aug 31, 2026

Summary not yet generated.

8-K Filed Aug 19, 2026 · Period ending Aug 17, 2026

Summary not yet generated.

Partner

Trade ETST commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

8-K Filed Aug 12, 2026 · Period ending Aug 11, 2026

Summary not yet generated.

10-Q Filed Aug 7, 2026 · Period ending Jun 30, 2026

Summary not yet generated.

8-K Filed Aug 7, 2026 · Period ending Aug 7, 2026

Summary not yet generated.

10-K Filed Jun 18, 2026 · Period ending Mar 31, 2026

Summary not yet generated.

8-K Filed Jun 18, 2026 · Period ending Jun 18, 2026

Summary not yet generated.

8-K Filed Jun 10, 2026 · Period ending Jun 10, 2026

Summary not yet generated.

8-K Filed Apr 17, 2026 · Period ending Apr 16, 2026

Summary not yet generated.

8-K Filed Mar 24, 2026 · Period ending Mar 24, 2026

Summary not yet generated.

10-Q Filed Feb 13, 2026 · Period ending Dec 31, 2025

Summary not yet generated.

10-Q Filed Nov 12, 2025 · Period ending Sep 30, 2025

Summary not yet generated.

10-K Filed Jun 27, 2025 · Period ending Mar 31, 2025

Summary not yet generated.

Latest financial statements

From 10-Q filed Aug 7, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.

As filed

Consolidated Statements of Operations (Unaudited)

Description 2026 2025
Revenue 9,025,779 8,760,190
Cost of Goods Sold 2,750,510 2,669,415
Gross Profit 6,275,269 6,090,775
Expenses
Salaries Expense 3,217,201 3,801,116
Selling general and administrative expenses 1,050,032 980,172
Bank charges 262,906 255,342
Advertising & marketing 850,004 633,926
Legal and professional fees 131,912 73,119
Insurance 33,571 44,293
Operating lease cost 45,043 -
Depreciation and amortization 66,861 34,563
Utilities 39,938 26,614
Total Expenses 5,697,468 5,849,144
Other income (expense)
Dividend and interest income 2,824 2,453
Net realized gain on sale of investments 365,537 81,586
Unrealized Gain on fair value changes of investments 19,374 135,316
Other 9,013 -
Interest Expense (16,197) (4,272)
Net Income before taxes 958,352 456,714
Income Taxes 242,655 -
Net Income 715,697 456,714
Net Loss attributed to non-controlling interest (8,495) (8,325)
Net Income available to common stockholders’ 724,192 465,039
Earnings per common share-Basic and Diluted 0.003 0.001
Weighted average number of shares outstanding- Basic and Diluted 290,000,679 294,508,894

Consolidated Balance Sheet (Unaudited)

Description As of June 30, 2026 As of March 31, 2026
ASSETS
Current Assets:
Cash and cash equivalents 631,118 796,797
Accounts receivable, net 845,945 356,054
-
Equity securities 2,184,154 1,360,040
Inventory 854,074 682,059
Long lived assets, available for sale 371,684 371,684
Prepaid expenses and other current assets 201,218 154,480
Total Current Assets 5,088,193 3,721,114
Non-Current Assets:
Property and equipment, net 1,498,431 1,517,888
Right of use assets, net 352,483 95,317
Intangible assets, net 202,182 208,170
Deferred tax asset, net 578,170 772,294
Goodwill 2,654,554 2,654,554
Total Assets 10,374,013 8,969,337
LIABILITIES AND EQUITY
Accounts payable 1,514,696 681,925
Accrued expenses and other payables 1,141,883 1,150,442
Current portion of operating lease obligations 213,969 96,206
Total Current Liabilities 2,870,548 1,928,573
Long-Term Liabilities:
Lease liability 139,195 -
Total Liabilities 3,009,743 1,928,573
Stockholders’ Equity:
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized; 1,000,000 and 1,000,000 shares issued and outstanding as of June 30, 2026, and March 31, 2026, respectively 1,000 1,000
Common stock, par value $0.001 per share, 300,000,000 shares authorized; 287,590,881 issued and outstanding, and 291,324,607 issued and outstanding as of June 30, 2026, and March 31, 2026, respectively 287,591 291,324
Additional paid-in capital 30,437,894 30,826,352
Accumulated deficit (23,384,007) (24,108,199)
Total Stockholders’ Equity 7,342,478 7,010,477
Non-Controlling interest (“NCI”) 21,792 30,287
Total Equity 7,364,270 7,040,764
Total Liabilities and Equity 10,374,013 8,969,337

Consolidated Statement of Cash Flows (Unaudited)

Description 2026 2025
Cash flows from operating activities:
Net Income 715,697 456,714
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 66,861 34,563
Unrealized loss on investments (19,374) (135,316)
Realized gain on sale of investments (365,537) (81,586)
Deferred income tax expense 194,124
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net (489,891) (212,580)
Prepaid expenses and other current assets (46,738) 195,600
Inventory (172,015) (265,551)
Accounts payable and accrued expenses and other 824,212 330,709
Lease liability, net (208) 16,823
Net cash provided by operating activities 707,131 339,376
Cash flows from investing activities:
Purchases of property and equipment, intangibles and long-lived assets available for sale (41,417) (232,220)
Purchase of investments (4,022,184) (1,309,785)
Sale of investments 3,582,982 1,285,054
Cash used for assets acquisition, net of cash acquired - (411,265)
Net cash used in investing activities (480,619) (668,216)
Cash flows from financing activities:
Payments on loans and obligations - (186,129)
Repurchase of common stock (392,191) (80,674)
Net Cash used in financing activities (392,191) (266,803)
Net decrease in cash and cash equivalents (165,679) (595,643)
Cash and cash equivalents at beginning of period 796,797 1,473,228
Cash and cash equivalents at period end 631,118 877,585
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest 16,197 14,984
Cash paid for income taxes 35,344 -
Non-Cash Transactions -
Initial recognition of right of use asset 298,955 187,058

Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗

About Earth Science Tech, Inc.

Source: Item 1 (Business) from the 10-K filed June 18, 2026. Description as filed by the company with the SEC.

ITEM
1. BUSINESS

BUSINESS
BACKGROUND AND OVERVIEW

Earth
Science Tech, Inc. (“ETST” or the “Company”) was incorporated under the laws of the State of Nevada on April
23, 2010, and subsequently redomiciled to the State of Florida on June 27, 2022, headquartered in Miami, Florida.

ETST
operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy
is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical
support, and patient fulfillment. The Company’s healthcare operations are supported by investments in real estate and
asset management activities and a consumer products business.

The
core of the Company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is
achieved through the synergy of specialized subsidiaries. The Company’s primary operating businesses include:

Business
/ Entity

Description

RxCompoundStore.com,
LLC (“RxCompound”)

Miami-based
licensed compounding pharmacy providing sterile and non-sterile medications in multiple U.S. states and Puerto Rico.

Mister
Meds, LLC (“MisterMeds”)

Abilene,
Texas compounding pharmacy that received full compounding licensure in March 2025; includes sterile compounding capabilities and
hazardous drug handling.

Peaks
Curative LLC(“Peaks”)

Telemedicine
referral platform offering asynchronous consultations for compounded medications prepared by RxCompound and Mister Meds.

Read full description ↓

DOConsultation.com
LLC (“DOC”)

Telehealth
brand focused on home-based therapies and virtual consultations, with prescriptions fulfilled by the Company’s pharmacies.

Las
Villas Health Care (“Villas”)

Brick-and-mortar
healthcare facility designed to expand patient access.

Avenvi
LLC

Real
estate and asset management arm; supports healthcare infrastructure and manages the Company’s share repurchase program.

MagneChef

80%-owned
direct-to-consumer kitchen products brand using proprietary intellectual property.

4

As
of the date of this filing, the Company has aggressively expanded its state licensure, allowing its pharmacy and telehealth services
to reach a near-national footprint.

Strategic
Asset Management & Infrastructure

Avenvi
serves as the Company’s real estate and asset management arm. Avenvi provides the critical physical infrastructure required for
the Company’s expanding pharmacy operations and manages ETST’s real estate-related investment strategies. Additionally, Avenvi
plays a pivotal role in the Company’s disciplined capital allocation strategy, which focuses on non-dilutive growth and the management
of the Company’s share repurchase initiatives.

Diversified
Holdings & Innovation

The
Company maintains a 80% stake in MagneChef, a direct-to-consumer brand that leverages proprietary intellectual property to market innovative
kitchen products. This subsidiary provides a diversified revenue stream and demonstrates the Company’s ability to commercialize
unique IP across different consumer segments.

Capital
Structure & Governance Focus

A
defining pillar of the Company’s current strategy is fiscal discipline and shareholder alignment. Since the final share issuance
in October 2023, management has focused exclusively on non-dilutive financing, significant reductions in authorized common stock (from
750 million to 300 million), and a robust share buyback program. This strategy is underpinned by a high level of insider ownership, with
management holding approximately 48% of outstanding shares, the vast majority of which were purchased.

5

PRODUCT
REGULATION

The
Company’s operations are subject to extensive federal, state, and local laws and regulations governing the compounding, distribution,
and delivery of pharmaceutical products, as well as the provision of telemedicine services and sale of consumer goods.

Pharmacy
Regulation

Our
pharmacy subsidiaries, RxCompound and Mister Meds are primarily governed by Section 503A of the Federal Food, Drug, and Cosmetic Act
(FDCA). Unlike large-scale manufacturers, our compounding pharmacies are regulated predominantly by individual State Boards of Pharmacy.
We maintain strict adherence to United States Pharmacopeia (USP) standards, specifically USP <795> for non-sterile preparations
and USP <797> for sterile preparations. These standards dictate the environmental controls, rigorous testing protocols, and quality
assurance measures necessary to ensure the integrity and potency of customized medications dispensed upon receipt of patient-specific
prescriptions. As we expand our geographical footprint, we continuously monitor state-level licensure requirements to ensure compliant
dispensing across all active jurisdictions.

Telemedicine
Regulation

The
Company’s digital health operations, facilitated through Peaks, DOC and our integrated pharmacy platforms, navigate a multifaceted
landscape of federal and state laws. We currently operate under the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities,
which permits our affiliated healthcare providers to prescribe Schedule II-V controlled substances via telemedicine through December
31, 2026, without a prior in-person evaluation. Furthermore, our business structures are meticulously designed to comply with state Corporate
Practice of Medicine (CPOM) doctrines, maintaining a clear separation between the Company’s administrative support and the independent
clinical judgment of licensed professionals. We also maintain comprehensive data security protocols to ensure all patient interactions
and records remain compliant with the Health Insurance Portability and Accountability Act (HIPAA).

Specialized
Clinical Services and Wellness

Villas
represents the Company’s commitment to personalized, in-person clinical care.
This subsidiary is subject to state-specific clinical licensure and must meet the stringent standards set by regional Departments of
Health for physical wellness facilities. In addition to medical board oversight, Villas adheres to Occupational Safety and Health Administration
(OSHA) standards regarding the management of clinical environments and the handling of medical waste. To ensure equitable access and
informed consent, the facility maintains rigorous language-access protocols, ensuring all clinical documentation and patient disclosures
meet federal standards for accuracy and cultural competence.

Asset
Management and Capital Allocation

Avenvi
serves as the strategic infrastructure and asset management arm of the Company, providing the logistical foundation for our pharmacy
operations while overseeing critical financial initiatives. In its capacity managing the Company’s $10 million share repurchase
program, Avenvi operates under the safe harbor provisions of SEC Rule 10b-18. This requires unwavering adherence to specific volume,
price, and timing constraints designed to maintain market integrity and prevent manipulative trading practices. Additionally, Avenvi
manages our physical properties to ensure compliance with local zoning ordinances and the specialized environmental codes required for
high-capacity compounding laboratories.

Consumer
Product Regulation

MagneChef,
our 80%-owned consumer brand, operates under the regulatory purview of agencies governing household goods and intellectual property.
Our products are subject to the safety standards enforced by the Consumer Product Safety Commission (CPSC) and the advertising substantiation
requirements of the Federal Trade Commission (FTC). Given that MagneChef’s value is derived from its proprietary magnetic heat-conduction
technology, we prioritize the maintenance and protection of our patent portfolio through regular filings with the U.S. Patent and Trademark
Office (USPTO). This ensures that our unique innovations remain legally protected as we scale our direct-to-consumer presence.

6

The
Company maintains internal compliance protocols and engages legal and regulatory consultants as needed to ensure adherence to applicable
laws and industry standards across all subsidiaries and operating areas.

Marketing

The
Company employs a multi-channel marketing and sales strategy designed to leverage the vertical integration of our healthcare and consumer
portfolios. Our approach focuses on high-conversion digital acquisition, strategic demographic targeting, and the utilization of proprietary
technology to drive patient retention and brand loyalty across our diverse subsidiaries. By maintaining control over both the clinical
consultation and the pharmaceutical fulfillment process, we are able to execute marketing campaigns that offer a seamless, high-value
consumer experience while maintaining a lower cost of customer acquisition (CAC) compared to non-integrated competitors.

Health
and Wellness

Our
marketing efforts for RxCompound, Mister Meds, and Peaks are centered on digital-first strategies that prioritize search engine optimization
(SEO), targeted social media engagement, and performance-based digital advertising. We focus on educating consumers about the clinical
benefits of customized compounding and the convenience of our asynchronous telemedicine platforms. For Mister Meds, our strategy specifically
targets high-demand therapeutic areas, utilizing data-driven insights to reach patients in licensed jurisdictions, such as Texas, where
we have established a strong dispensing presence. Peaks and DOC serve as a primary funnel for these operations, utilizing a streamlined
user interface to convert digital traffic into long-term patients through a frictionless onboarding and consultation process.

Our strategy for Villas emphasizes community-based outreach, culturally relevant digital content, and targeted traditional media to build
trust within its niche market. By focusing on specialized wellness and sexual health—areas often underserved by traditional healthcare
providers—Villas attracts a dedicated patient base that values personalized, in-person clinical support. This subsidiary also benefits
from cross-promotional opportunities within the broader ETST ecosystem, directing patients to our digital pharmacy services for ongoing
prescription fulfillment.

Real
Estate and Asset Management Division

Avenvi
has no marketing activities as it serves as foundation for managing the Company’s assets.

Consumer
Products

The
marketing strategy for MagneChef leverages the brand’s proprietary intellectual property to differentiate its products in the competitive
direct-to-consumer (DTC) kitchenware market. We utilize a combination of influencer partnerships, video-based social media demonstrations,
and e-commerce optimization to showcase the unique benefits of our magnetic heat-conduction technology. By focusing on the “innovative
kitchen” segment, MagneChef targets a demographic that values efficiency and high-performance technology, allowing us to maintain
premium pricing and drive brand recognition independent of our healthcare operations.

7

The
Company adheres to all applicable advertising regulations across its marketing channels, including those governing the promotion of health-related
products and services. Marketing compliance is reviewed internally and through third-party consultants to reduce regulatory risk and
ensure alignment with corporate messaging.

Strategic
Brand Positioning and Retention

Central
to the Company’s overall marketing success is our focus on patient and customer retention. We utilize Customer Relationship
Management (CRM) systems at each of our subsidiaries to provide personalized follow-ups, medication reminders, and targeted wellness content.
This holistic approach not only increases the lifetime value (LTV) of each customer but also reinforces ETST’s position as a comprehensive
health and wellness provider. Furthermore, our commitment to social responsibility through the ESF enhances our brand equity, demonstrating
to investors and consumers alike that the Company is dedicated to healthcare accessibility and community support.

COMPETITION

The
Company operates in a highly competitive and fragmented landscape across several major sectors, including pharmaceutical compounding,
telemedicine, clinical wellness, real estate asset management, and direct-to-consumer goods. We compete with a diverse array of market
participants, ranging from large, established multinational corporations with significantly greater financial resources to specialized,
niche firms and emerging technology-driven startups. Our ability to compete effectively is predicated on our unique vertical integration,
which allows us to offer a value added healthcare experience.

Health
and wellness

In
the pharmaceutical compounding and telemedicine sectors the Company faces intense competition from both traditional brick-and-mortar
pharmacies and a rapidly expanding cohort of digital health platforms. The Company competes with established pharmacy chains, which have increasingly integrated specialty pharmacy and
digital prescription services into their models. In the telemedicine space, we compete with well-capitalized platforms as well as specialized sexual health and wellness platforms.
Our competitive advantage in this sector lies in our ability to seamlessly link the clinical consultation with our proprietary pharmacy
fulfillment, ensuring higher quality control and more responsive patient care than platforms that rely on third-party pharmacy networks.

Real
Estate and Asset Management

Avenvi
has no natural competitors as it serves as the foundation for managing the Company’s assets.

Consumer
Product Innovation

MagneChef
operates in the highly saturated direct-to-consumer (DTC) kitchenware and household goods market. We compete with established premium
cookware brands, as well as high-growth DTC entrants. These
competitors often have larger marketing budgets and established retail partnerships. MagneChef’s competitive strategy focuses on
the commercialization of its proprietary magnetic heat-conduction technology, allowing us to market a unique value proposition centered
on efficiency and technological innovation. By targeting the “innovative kitchen” segment through digital-first performance
marketing, we aim to capture market share from consumers seeking high-performance alternatives to traditional cookware.

8

Across
all business segments, the Company’s ability to compete effectively depends on its continued investment in operational scalability,
regulatory compliance, customer service, and innovation. The Company expects competitive pressures to intensify as regulatory frameworks
evolve, and new market entrants emerge.

EMPLOYEES

As
of March 31, 2026, the Company has 77 employees. None of our employees are represented by a union or covered by a collective bargaining
agreement. We have not experienced any work stoppages, and we consider our relationship with our employees to be good.